CY1105780T1 - Ετepο-δικυκλικοi crf ανταγωνιστeς - Google Patents
Ετepο-δικυκλικοi crf ανταγωνιστeςInfo
- Publication number
- CY1105780T1 CY1105780T1 CY20061101650T CY061101650T CY1105780T1 CY 1105780 T1 CY1105780 T1 CY 1105780T1 CY 20061101650 T CY20061101650 T CY 20061101650T CY 061101650 T CY061101650 T CY 061101650T CY 1105780 T1 CY1105780 T1 CY 1105780T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- halogen
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- -1 -NR 6 R 7 Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- External Artificial Organs (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I) συμπεριλαμβανομένων στερεο-ισομερών, προ-φαρμάκων και από φαρμακευτικής άποψης αποδεκτών αλάτων ή διαλυτοποιημένων μορφών αυτών, όπου το R είναι αρύλιο ή ετεροαρύλιο, κάθε ένα εκ των οποίων μπορεί να είναι υποκατεστημένο από 1 έως 4 ομάδες που επιλέγονται από: αλογόνο, C1-C6 αλκύλιο, C1-C6 αλκοξυ-ομάδα, αλογόνο-C1-C6 αλκύλιο, C2-C6 αλκενύλιο, C2-C6 αλκυνύλιο, αλογόνο-C1-C6 αλκοξυ-ομάδα, -C(O)R5, νιτρο-ομάδα, -NR6R7, κυανο-ομάδα, και μια ομάδα R8. To R1 είναι υδρογόνο, C1-C6 αλκύλιο, C2-C6 αλκενύλιο, C2-C6 αλκυνύλιο, αλογόνο-C1-C6 αλκύλιο, αλογόνο-C1-C6 αλκοξυ-ομάδα, αλογόνο, NR6R7 ή κυανο-ομάδα. To R2 είναι υδρογόνο, C3-C7 κυκλοαλκύλιο ή μια ομάδα R9. To R3 είναι C3-C7 κυκλοαλκύλιο ή μια ομάδα R9 ή τα R2 και R3 σχηματίζουν μαζί με το Ν μια 5-14-μελή ετεροκυκλική ένωση, η οποία μπορεί να είναι υποκατεστημένη από 1 έως 3 ομάδες R10. To R4 είναι υδρογόνο, C1-C6 αλκύλιο, αλογόνο ή αλογόνο-01-06 αλκύλιο. To R5 είναι ένα C1-C4 αλκύλιο, -OR6 ή NR6R7. To R6 είναι υδρογόνο ή C1-C6 αλκύλιο, το R7 είναι υδρογόνο ή C1-C6 αλκύλιο. To R8 είναι μια 5-6-μελής ετεροκυκλική ένωση, η οποία μπορεί να είναι κορεσμένη ή να περιέχει ένα έως τρεις διπλούς δεσμούς και μπορεί να είναι υποκατεστημένη από 1 ή περισσότερες ομάδες R11. To R9 είναι ένα C1-C6 αλκύλιο το οποίο μπορεί να είναι υποκατεστημένο από μία ή περισσότερες ομάδες που επιλέγονται από: C3-C7 κυκλοαλκύλιο, C1-C6 αλκοξυ-ομάδα, αλογόνο-C1-C6 αλκοξυ-ομάδα, υδροξυ-ομάδα, αλογόνο-C1-C6 αλκύλιο. To R10 είναι μια ομάδα R8, C3-C7 κυκλοαλκύλιο, C1-C6 αλκύλιο, C1-C6 αλκοξυ-ομάδα, αλογόνο-C1-C6 αλκύλιο, C2-C6 αλκενύλιο, C2-C6 αλκυνύλιο, αλογόνο-C1-C6 αλκοξυ-ομάδα, υδροξυ-ομάδα, αλογόνο, νιτρο-ομάδα, κυανο-ομάδα, C(O)NR6R7, φαινύλιο που μπορεί να είναι υποκατεστημένο από 1 έως 4 ομάδες R11. To R11 είναι C3-C7 κυκλοαλκύλιο, C1-C6 αλκύλιο, C1-C6 αλκοξυ-ομάδα, αλογόνο-C1-C6 αλκύλιο, C2-C6 αλκενύλιο, C2-C6 αλκυνύλιο, αλογόνο-C1-C6 αλκοξυ-ομάδα, υδροξυ-ομάδα, αλογόνο, νιτρο-ομάδα, κυανο-ομάδα ή C(O)NR6R7. To Χ είναι άνθρακας ή άζωτο, το n είναι 1 ή 2. Η παρούσα εφεύρεση αφορά μεθόδους παρασκευής τους, φαρμακευτικές συνθέσεις περιέχουσες αυτές και τη χρησιμοποίηση τους στη θεραπευτική αγωγή καταστάσεων, στις οποίες μεσολαβεί ο παράγοντας έκλυσης κορτικοτροπίνης [corticotropin-releasing factor (CRF)].
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117396.2A GB0117396D0 (en) | 2001-07-17 | 2001-07-17 | Chemical compounds |
| PCT/EP2002/007865 WO2003008412A2 (en) | 2001-07-17 | 2002-07-15 | Hetero-bicyclic crf antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105780T1 true CY1105780T1 (el) | 2011-02-02 |
Family
ID=9918655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101650T CY1105780T1 (el) | 2001-07-17 | 2006-11-14 | Ετepο-δικυκλικοi crf ανταγωνιστeς |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7253284B2 (el) |
| EP (2) | EP1425280B1 (el) |
| JP (1) | JP4459616B2 (el) |
| KR (2) | KR20090110386A (el) |
| CN (1) | CN100447141C (el) |
| AT (2) | ATE461197T1 (el) |
| AU (1) | AU2002328899B2 (el) |
| BR (1) | BR0211171A (el) |
| CA (1) | CA2451530A1 (el) |
| CO (1) | CO5550437A2 (el) |
| CY (1) | CY1105780T1 (el) |
| DE (2) | DE60214401T2 (el) |
| DK (1) | DK1425280T3 (el) |
| ES (2) | ES2342417T3 (el) |
| GB (2) | GB0117396D0 (el) |
| HU (1) | HUP0400465A2 (el) |
| IL (1) | IL159254A0 (el) |
| MX (1) | MXPA04000494A (el) |
| NO (1) | NO20040206L (el) |
| NZ (1) | NZ530043A (el) |
| PL (1) | PL368053A1 (el) |
| PT (1) | PT1425280E (el) |
| RU (1) | RU2310655C2 (el) |
| SI (1) | SI1425280T1 (el) |
| WO (1) | WO2003008412A2 (el) |
| ZA (1) | ZA200309708B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004533465A (ja) * | 2001-06-12 | 2004-11-04 | グラクソ グループ リミテッド | コルチコトロピン放出因子アンタゴニスト |
| ATE359782T1 (de) * | 2003-01-16 | 2007-05-15 | Sb Pharmco Inc | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| MY143499A (en) | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
| EP1802621B1 (en) * | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US8088779B2 (en) | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| US8513420B2 (en) | 2007-03-19 | 2013-08-20 | Monika Mazik | Amino-naphthyridine derivatives |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009008552A1 (en) * | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO152788C (no) * | 1978-08-31 | 1985-11-20 | Otsuka Pharma Co Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinylbenzoheterocykliske forbindelser. |
| US5169857A (en) | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| GB2248618B (en) | 1988-06-17 | 1993-01-06 | Wyeth John & Brother Ltd | Process for preparing pyridine derivatives |
| CA2022408A1 (en) | 1989-08-31 | 1991-03-01 | Michael P. Bodman | Process for preparing pyridine carboxylic acid derivatives |
| ES2087916T3 (es) | 1989-10-11 | 1996-08-01 | Teijin Ltd | Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo. |
| DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
| AU665184B2 (en) | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| FI944602A0 (fi) | 1992-04-03 | 1994-10-03 | Upjohn Co | Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| NZ274978A (en) | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| PL181895B1 (pl) | 1994-06-16 | 2001-10-31 | Pfizer | Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| AU738304B2 (en) | 1995-10-13 | 2001-09-13 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands |
| SK14099A3 (en) | 1996-08-06 | 2000-05-16 | Pfizer | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
| WO1998035967A2 (en) | 1997-02-18 | 1998-08-20 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
| CN1264381A (zh) | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药 |
| JP2002510687A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| JPH11335376A (ja) | 1998-05-25 | 1999-12-07 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| JP2000086663A (ja) | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| EP1165555B1 (en) | 1999-03-11 | 2003-07-16 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| JP2002540203A (ja) | 1999-03-29 | 2002-11-26 | ニューロゲン コーポレイション | Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体 |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| JP2002543200A (ja) | 1999-04-30 | 2002-12-17 | ニューロゲン コーポレイション | ９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド |
| OA12050A (en) | 1999-09-30 | 2006-05-02 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles. |
| US6525067B1 (en) | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
| MXPA02007047A (es) | 2000-01-18 | 2002-12-13 | Pfizer Prod Inc | Antagonista del factor liberador de corticotropina. |
| AR028782A1 (es) | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| WO2002019975A1 (fr) | 2000-09-05 | 2002-03-14 | Taisho Pharmaceutical Co., Ltd. | Stimulants de la croissance des cheveux |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| CA2446514A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| JP2004533465A (ja) | 2001-06-12 | 2004-11-04 | グラクソ グループ リミテッド | コルチコトロピン放出因子アンタゴニスト |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| ATE359782T1 (de) | 2003-01-16 | 2007-05-15 | Sb Pharmco Inc | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten |
| JP2006517966A (ja) | 2003-02-14 | 2006-08-03 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体 |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-07-17 GB GBGB0117396.2A patent/GB0117396D0/en not_active Ceased
-
2002
- 2002-07-11 GB GB0216041A patent/GB2378702A/en not_active Withdrawn
- 2002-07-15 ES ES06076176T patent/ES2342417T3/es not_active Expired - Lifetime
- 2002-07-15 PT PT02764696T patent/PT1425280E/pt unknown
- 2002-07-15 AT AT06076176T patent/ATE461197T1/de not_active IP Right Cessation
- 2002-07-15 SI SI200230419T patent/SI1425280T1/sl unknown
- 2002-07-15 CN CNB02813866XA patent/CN100447141C/zh not_active Expired - Fee Related
- 2002-07-15 HU HU0400465A patent/HUP0400465A2/hu unknown
- 2002-07-15 KR KR1020097020632A patent/KR20090110386A/ko not_active Ceased
- 2002-07-15 DK DK02764696T patent/DK1425280T3/da active
- 2002-07-15 KR KR1020047000696A patent/KR100961287B1/ko not_active Expired - Fee Related
- 2002-07-15 AU AU2002328899A patent/AU2002328899B2/en not_active Ceased
- 2002-07-15 AT AT02764696T patent/ATE338042T1/de not_active IP Right Cessation
- 2002-07-15 WO PCT/EP2002/007865 patent/WO2003008412A2/en not_active Ceased
- 2002-07-15 DE DE60214401T patent/DE60214401T2/de not_active Expired - Lifetime
- 2002-07-15 EP EP02764696A patent/EP1425280B1/en not_active Expired - Lifetime
- 2002-07-15 IL IL15925402A patent/IL159254A0/xx unknown
- 2002-07-15 DE DE60235729T patent/DE60235729D1/de not_active Expired - Lifetime
- 2002-07-15 EP EP06076176A patent/EP1695974B1/en not_active Expired - Lifetime
- 2002-07-15 NZ NZ530043A patent/NZ530043A/xx unknown
- 2002-07-15 CA CA002451530A patent/CA2451530A1/en not_active Abandoned
- 2002-07-15 JP JP2003513971A patent/JP4459616B2/ja not_active Expired - Fee Related
- 2002-07-15 PL PL02368053A patent/PL368053A1/xx unknown
- 2002-07-15 ES ES02764696T patent/ES2271327T3/es not_active Expired - Lifetime
- 2002-07-15 US US10/483,792 patent/US7253284B2/en not_active Expired - Fee Related
- 2002-07-15 MX MXPA04000494A patent/MXPA04000494A/es active IP Right Grant
- 2002-07-15 RU RU2004104349/04A patent/RU2310655C2/ru not_active IP Right Cessation
- 2002-07-15 BR BR0211171-3A patent/BR0211171A/pt not_active IP Right Cessation
-
2003
- 2003-12-15 ZA ZA200309708A patent/ZA200309708B/xx unknown
-
2004
- 2004-01-16 CO CO04002410A patent/CO5550437A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040206A patent/NO20040206L/no not_active Application Discontinuation
-
2006
- 2006-11-14 CY CY20061101650T patent/CY1105780T1/el unknown
-
2007
- 2007-05-16 US US11/749,433 patent/US20070219232A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105780T1 (el) | Ετepο-δικυκλικοi crf ανταγωνιστeς | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| CY1107532T1 (el) | Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4) | |
| CY1112941T1 (el) | Δικυκλικοι αναστολεις της μεκ | |
| CY1108025T1 (el) | Παραγωγα n-[φαινυλο (πιπεριδινο-2-υλο)μεθυλο] βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη | |
| CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
| AR040870A1 (es) | Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende | |
| CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
| HUP0203438A2 (hu) | Foszfodiészteráz gátló hatású 5-(2-helyettesített-5-heterociklilszulfonilpirid-3-il)-dihidropirazolo[4,3-d]-pirimidin-7-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| SA521430330B1 (ar) | Eed و rc2 مشتقات آزولوبيريدين كبيرة الحلقة كمعدلات | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. | |
| CY1114240T1 (el) | Παραγωγα σουλφοναμιδιου τετραϋδροϊσοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη | |
| HUP0401499A2 (hu) | Indolszármazékok, mint COX II inhibítorok | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. | |
| AR066956A1 (es) | Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas. | |
| ATE397609T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
| DE602007003997D1 (de) | 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen | |
| PE20220280A1 (es) | Inhibidores de arginasa y metodos de uso de estos |